Blood Samples to Identify Biomarkers of Busulfan
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02291965|
Recruitment Status : Active, not recruiting
First Posted : November 17, 2014
Last Update Posted : May 5, 2020
Specific Aim 1: To determine whether endogenous metabolomics-based biomarkers obtained before IV BU administration can predict IV BU clearance.
Specific Aim 2: To characterize IV BU metabolism by metabolomics.
Specific Aim 3: To identify covariates influencing IV BU pharmacokinetics.
|Condition or disease|
|Leukemia Lymphoma Multiple Myeloma Immunodeficiency Myelodysplastic Syndrome|
|Study Type :||Observational|
|Actual Enrollment :||139 participants|
|Official Title:||Optimizing Busulfan: Efficacy, Toxicity, and Pharmacometabolomics|
|Actual Study Start Date :||November 2014|
|Actual Primary Completion Date :||April 20, 2019|
|Estimated Study Completion Date :||May 31, 2023|
- Busulfan clearance [ Time Frame: 24 hours after start of busulfan ]
- Overall survival [ Time Frame: 1 year ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02291965
|United States, Washington|
|University of Washington|
|Seattle, Washington, United States, 98105|
|Principal Investigator:||Jeannine S. McCune, PharmD||University of Washington|